Terms: = Liver cancer AND ELF4, MEF, 2000, ENSG00000102034, ELFR, RP3-510O21_2, Q99607 AND Clinical Outcome
727 results:
1. COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma.
Liu J; Han D; Xuan J; Xie J; Wang W; Zhou Q; Chen K
Aging (Albany NY); 2024 Mar; 16(6):5264-5287. PubMed ID: 38466642
[TBL] [Abstract] [Full Text] [Related]
2. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of clinical outcome between laparoscopic and open hepatectomy of high difficulty score for hepatocellular carcinoma: a propensity score analysis.
Ng KKC; Cheng KC; Kung JWC; Ho KM; Lok HT; Fung AKY; Chong CCN; Cheung SYS; Lee KF; Wong J; Lai PBS
Surg Endosc; 2024 Feb; 38(2):857-871. PubMed ID: 38082015
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
[TBL] [Abstract] [Full Text] [Related]
5. Development and evaluation of a risk score model based on a WNT score gene-associated signature for predicting the clinical outcome and the tumour microenvironment of hepatocellular carcinoma.
Li P; Ma X; Huang D; Gu X
Int J Immunopathol Pharmacol; 2023; 37():3946320231218179. PubMed ID: 38054921
[No Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
Li J; Delamarre A; Wong VW; de Lédinghen V
United European Gastroenterol J; 2024 Mar; 12(2):219-225. PubMed ID: 37987101
[TBL] [Abstract] [Full Text] [Related]
8. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract] [Full Text] [Related]
9. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
Amin MN; El-Far YM; El-Mowafy M; Elgaml A
Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
[TBL] [Abstract] [Full Text] [Related]
10. 10 years, 100 robotic major hepatectomies: a single-center experience.
McCarron F; Cochran A; Ricker A; Mantha R; Driedger M; Beckman M; Vrochides D; Martinie J
Surg Endosc; 2024 Feb; 38(2):902-907. PubMed ID: 37845533
[TBL] [Abstract] [Full Text] [Related]
11. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
12. Limiting viral replication in hepatocytes alters Rift Valley fever virus disease manifestations.
Xu L; Paine AC; Barbeau DJ; Alencastro F; Duncan AW; McElroy AK
J Virol; 2023 Sep; 97(9):e0085323. PubMed ID: 37695055
[TBL] [Abstract] [Full Text] [Related]
13. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of CD73 is associated with recurrence and poor prognosis of gingivobuccal oral cancer as revealed by transcriptome and deep immune profiling of paired tumor and margin tissues.
Chatterjee A; Chaudhary A; Ghosh A; Arun P; Mukherjee G; Arun I; Maitra A; Biswas N; Majumder PP
Cancer Med; 2023 Aug; 12(16):16774-16787. PubMed ID: 37392167
[TBL] [Abstract] [Full Text] [Related]
15. Geriatric Nutritional Risk Index and the Survival of Patients with Hepatocellular Carcinoma: A Meta-Analysis.
Xu X; Kang F; Zhang N; Niu Y; Jia J
Horm Metab Res; 2023 Oct; 55(10):692-700. PubMed ID: 37385295
[TBL] [Abstract] [Full Text] [Related]
16. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
[TBL] [Abstract] [Full Text] [Related]
17. Transarterial chemoembolization
Yang B; Yuan M; Yang T; Liao Z; Wu H
Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
[TBL] [Abstract] [Full Text] [Related]
18. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
19. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer.
Desoteux M; Maillot B; Bévant K; Ferlier T; Leroux R; Angenard G; Louis C; Sulpice L; Boudjema K; Coulouarn C
FEBS Open Bio; 2023 Jul; 13(7):1278-1290. PubMed ID: 37195148
[TBL] [Abstract] [Full Text] [Related]
[Next]
